Table 1 Patients’ characteristics
Comparison of ESBL-producing E. coli and K. pneumoniae faecal carriers | |||
|---|---|---|---|
ESBL-producing E. coli (n = 11) | ESBL-producing K. pneumoniae (n = 6) | p-value | |
Characteristics at admission to ICU | |||
Age (years) | 77 [66–84] | 76 [57–84] | 0.80 |
Sex (male) | 7/11 | 5/6 | 0.60 |
Proton pump inhibitor | 2/11 | 1/6 | 1.00 |
Metformin | 1/11 | 0/6 | 1.00 |
Hospitalization within the 3 previous months | 6/11 | 5/6 | 0.33 |
Median (IQR) length of stay (days) | 5 [3–12] | 7 [6–12] | 0.36 |
Cause of previous hospitalization | Urinary sepsis: 2 Stroke: 1 Heart failure: 1 Infective endocarditis: 1 Acute hepatitis: 1 | Stroke: 1 ACS: 1 Uncompensated diabetes: 1 Diabetic foot ulcer: 1 R-CHOP cures: 1 | – |
Antimicrobial treatment within the 3 previous months | 4/11 Piperacillin/tazobactam: 2 Amoxicilline: 2 Clavulanic acid + amoxicillin: 1 | 2/6 Piperacillin/tazobactam – linezolide – amikacin: 1 Meropenem – amikacin: 1 | 0.64 |
Cause of admission | 0.43 | ||
Septic shock | 4 | 1 | |
Hypoxemic ARF | 3 | 1 | |
Coma | 2 | 2 | |
Hypercapnic ARF | 1 | 0 | |
Cardiac arrest | 1 | 1 | |
Cardiogenic shock | 0 | 1 | |
SAPS II | 55 [31–68] | 80 [68–87] | 0.007 |
Septic shock | 3/11 | 2/6 | 1.00 |
ARDS | 1/11 | 1/6 | 1.00 |
Acute kidney injury | 2/11 | 6/6 | 0.002 |
Outcomes | |||
ICU-mortality | 1/11 | 2/6 | 0.51 |
Comparison of ESBL-producing E. coli and matched non ESBL-E faecal carriers | |||
|---|---|---|---|
ESBL-producing E. coli (n = 11) | matched non ESBL-E (n = 22) | p-value | |
Characteristics at admission to ICU | |||
Age (years) | 77 [66–84] | 74 [65–78] | 0.48 |
Sex (male) | 7/11 | 14/22 | 1.00 |
Proton pump inhibitor | 2/11 | 6/22 | 0.69 |
Metformin | 1/11 | 3/22 | 1.00 |
Hospitalization within the 3 previous months | 6/11 | 13/22 | 1.00 |
Median (IQR) length of stay (days) | 5 [3–12] | 13 [23–30] | < 0.01 |
Cause of previous hospitalization | Urinary sepsis: 2 Stroke: 1 Heart failure: 1 Infective endocarditis: 1 Acute hepatitis: 1 | Stroke: 3 Pneumonia: 2 ACS: 2 Heart failure: 1 Acute limb ischemia: 1 AECOPD: 1 Chest trauma: 1 Epilepsy: 1 Spine surgery: 1 | |
Antimicrobial treatment within the 3 previous months | 4/11 Piperacillin/tazobactam: 2 Amoxicilline: 2 Clavulanic acid + amoxicillin: 1 | 9/22 Amoxicilline: 3 Spiramycin: 2 Levofloxacine: 2 3rd generation cephalosporin: 1 Clavulanic acid + amoxicillin: 1 | 1.00 - |
SAPS II | 55 [31–68] | 70 [45–78] | 0.10 |
Septic shock | 3/11 | 10/22 | 0.46 |
ARDS | 1/11 | 2/22 | 1.00 |
Acute kidney injury | 2/11 | 14/22 | 0.03 |
Outcomes | |||
ICU-mortality | 1/11 | 5/22 | 0.64 |
ESBL-producing K. pneumoniae and matched non ESBL-E faecal carriers | |||
|---|---|---|---|
ESBL-producing K. pneumoniae(n = 6) | matched non ESBL-E (n = 12) | p-value | |
Characteristics at admission to ICU | |||
Age (years) | 76 [57–84] | 74 [66–81] | 0.89 |
Sex (male) | 5/6 | 10/12 | 1.00 |
Proton pump inhibitor | 1/6 | 5/12 | 0.60 |
Metformin | 0/6 | 1/12 | 1.00 |
Hospitalization within the 3 previous months | 5/6 | 7/12 | 0.60 |
Median (IQR) length of stay (days) | 7 [6–12] | 12 [5–17] | 0.46 |
Cause of previous hospitalization | Stroke: 1 ACS: 1 Uncompensated diabetes: 1 Diabetic foot ulcer: 1 R-CHOP cures: 1 | Stroke: 1 Heart failure: 1 Pneumonia: 1 AECOPD: 1 Epilepsy: 1 Kidney transplantation: 1 Digestive surgery: 1 | - |
SAPS II | 80 [68–87] | 65 [54–77] | 0.08 |
Septic shock | 2/6 | 3/12 | 1.00 |
ARDS | 1/6 | 4/12 | 0.61 |
Acute kidney injury | 6/6 | 7/12 | 0.11 |
Antimicrobial treatment during the 3 previous months | 2/6 Piperacillin/tazobactam—linezolide—amikacin: 1 Meropenem—amikacin: 1 | 3/12 Amoxicilline: 2 Clavulanic acid + amoxicilline: 1 | 0.34 - |
Outcomes | |||
ICU-mortality | 2/6 | 3/12 | 1.00 |